Jump to content

Ramosetron: Difference between revisions

Browse history interactively
Page 1
Page 2
← Previous edit
Content deleted Content added
VisualWikitext
Adding reference for treatment of diarrhea-predominant irritable bowel syndrome in males + one minor edit (male => males).
The quantity of lactose contained within this medication is so low, it is unlikely to trigger most people's symptoms. Loperamide, one of the most popular IBS drugs, also contains lactose. Therefore, this sentence doesn't make much sense to include and should be removed.
 
(41 intermediate revisions by 25 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
⚫
| IUPAC_name = (1-methyl-1''H''-indol-3-yl)[(5''R'')-4,5,6,7-tetrahydro-1''H''-benzimidazol-5-yl]methanone
| Watchedfields = changed
⚫
| image = Ramosetron.svg
| verifiedrevid = 377074289
⚫
| CAS_number = 132907-72-3
⚫
| IUPAC_name = (1-Methyl-1''H''-indol-3-yl)[(5''R'')-4,5,6,7-tetrahydro-1''H''-benzimidazol-5-yl]methanone
| CAS_supplemental =
⚫
| image = Ramosetron.svg
⚫
| ATC_prefix = none

⚫
| ATC_suffix =
<!--Clinical data-->
⚫
| ATC_supplemental =
| tradename =
⚫
| PubChem = 108000
| Drugs.com = {{drugs.com|international|ramosetron}}
⚫
| DrugBank =
⚫
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫
| chemical_formula =
⚫
| pregnancy_US = <!-- A / B / C / D / X -->
⚫
| C=17 | H=17 | N=3 | O=1
⚫
| pregnancy_category =
| molecular_weight = 279.33 g/mol
⚫
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
⚫
| bioavailability =
⚫
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫
| protein_bound =
⚫
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
⚫
| metabolism =
⚫
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫
| legal_status =
| routes_of_administration = [[Oral administration|By mouth]] ([[Orally disintegrating tablet|ODT]]), [[Intravenous therapy|IV]]

<!--Pharmacokinetic data-->
⚫
| bioavailability =
⚫
| protein_bound =
⚫
| metabolism =
| elimination_half-life = 5.8 hours
| elimination_half-life = 5.8 hours
| excretion =
| excretion =

⚫
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
<!--Identifiers-->
⚫
| pregnancy_US = <!-- A / B / C / D / X -->
| index_label =
⚫
| pregnancy_category=

⚫
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| index2_label = HCl
⚫
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| CAS_number2_Ref = {{cascite|correct|CAS}}
⚫
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| CAS_number2 = 132907-72-3
⚫
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| UNII2_Ref = {{fdacite|correct|FDA}}
⚫
| legal_status =
| UNII2 = 9551LHD87E
| routes_of_administration = [[Intravenous therapy|Intravenous]]

| CAS_number_Ref = {{cascite|correct|??}}
⚫
| CAS_number = 132036-88-5
⚫
| ATC_prefix = None
⚫
| ATC_suffix =
⚫
| ATC_supplemental =
⚫
| PubChem = 108000
| IUPHAR_ligand2 = 2305
| IUPHAR_ligand = 2301
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
⚫
| DrugBank =
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 7ZRO0SC54Y
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1643895
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 97112
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D02016

<!--Chemical data-->
⚫
| chemical_formula =
⚫
| C=17 | H=17 | N=3 | O=1
| smiles = CN1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C17H17N3O/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14/h2-5,9-11H,6-8H2,1H3,(H,18,19)/t11-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = NTHPAPBPFQJABD-LLVKDONJSA-N
}}
}}
⚫
'''Ramosetron''' ([[International Nonproprietary Name|INN]]) is a [[serotonin]] [[5-HT3 antagonist|5-HT<sub>3</sub> receptor antagonist]] for the treatment of nausea and vomiting.<ref>{{cite journal |author=Fujii Y, Saitoh Y, Tanaka H, Toyooka H |title=Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery |journal=Anesth. Analg. |volume=90 |issue=2 |pages=472–5 |year=2000 |month=February |pmid=10648342 |doi= 10.1097/00000539-200002000-00043|url=http://www.anesthesia-analgesia.org/cgi/pmidlookup?view=long&pmid=10648342}}</ref> Ramosetron is also indicated for a treatment of “diarrhea-predominant irritable bowel syndrome in males”.<ref>http://www.astellas.com/en/corporate/news/detail/astellas-launches-irribow-for.html</ref> In India it is marketed under the brand name of '''"IBset"'''.


⚫
'''Ramosetron''' ([[International Nonproprietary Name|INN]]) is a [[serotonin]] [[5-HT3 antagonist|5-HT<sub>3</sub> receptor antagonist]] for the treatment of nausea and vomiting.<ref>{{cite journal |vauthors=Fujii Y, Saitoh Y, Tanaka H, Toyooka H |title=Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery |journal=Anesth. Analg. |volume=90 |issue=2 |pages=472–5 |date=February 2000 |pmid=10648342 |doi= 10.1097/00000539-200002000-00043|url=http://www.anesthesia-analgesia.org/cgi/pmidlookup?view=long&pmid=10648342|doi-access=free }}</ref> Ramosetron is also indicated for a treatment of "diarrhea-predominant irritable bowel syndrome in male and women".<ref>{{cite web|url=http://www.astellas.com/en/corporate/news/detail/astellas-launches-irribow-for.html|title=2008 News Releases - Astellas Pharma Inc.|website=www.astellas.com}}</ref> In India it is marketed under the brand name of '''Ibset'''.


It is only licensed for use in [[Japan]] and selected [[Southeast Asia]]n countries. It is commonly sold under the tradename '''Nasea''' and in India as '''Nozia''' (300 mcg/ml Inj. & 100 mcg Tab.) <ref>[http://www.mims-online.com/Page.aspx?menuid=mng&name=Nasea+amp Abriged prescribing information - Nasea (MIMS Philippines)]. Retrieved on June 13, 2008.</ref>
It is only licensed for use in [[Japan]] and selected [[Southeast Asia]]n countries. In Japan it is sold under the trade name '''Irribow'''.<ref>[http://www.qlife.jp/meds/rx13938.html Summary in Japanese]. Retrieved on September 4, 2012.</ref><ref>{{Cite web|url=https://www.astellas.com/en/corporate/news/detail/approval-of-irribow-od-tablets.html|title=2013 News Releases {{!}} Astellas Pharma Inc.|website=www.astellas.com|language=en|access-date=2018-04-06}}</ref> and in India as '''Ibset''' . 'Elsewhere it is commonly sold under the trade name '''Nasea''' and in India as '''Nozia''' (150 μg/mL injection & 100 μg oral tablet).<ref>[http://www.mims-online.com/Page.aspx?menuid=mng&name=Nasea+amp Abridged prescribing information — Nasea (MIMS Philippines)]{{Dead link|date=December 2023 |bot=InternetArchiveBot |fix-attempted=yes }}. Retrieved on June 13, 2008.</ref>


==References==
==References==
Line 36: Line 73:


{{5-HT3 antagonists}}
{{5-HT3 antagonists}}
{{Drugs for functional gastrointestinal disorders}}
{{Serotonergics}}
{{Serotonergics}}


[[Category:Antiemetics]]
[[Category:Antiemetics]]
⚫
[[Category:Benzimidazoles]]
[[Category:5-HT3 antagonists]]
[[Category:5-HT3 antagonists]]
[[Category:Indoles]]
[[Category:Indoles]]
⚫
[[Category:Benzimidazoles]]
[[Category:Ketones]]
[[Category:Ketones]]



{{gastrointestinal-drug-stub}}
{{gastrointestinal-drug-stub}}

[[ja:ラモセトロン]]
[[pt:Ramosetrona]]
Retrieved from "https://en.wikipedia.org/wiki/Special:ComparePages"